Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

denosumab

View Patient Information
A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:denosumab biosimilar LY01011
denosumab biosimilar MW032
denosumab biosimilar QL1206
denosumab biosimilar TK-006
US brand name:Prolia
Xgeva
Foreign brand name:Prolia
Code name:AMG 162
AMG-162
TK-006
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search